[EMAIL PROTECTED] wrote:
>
><http://us.f1.yahoofs.com/users/1e1000e9/bc/friends/__hr_HEADER4.jpg?bc0nix8A5efRG04T>
>
>
>
> *Special Alert : WASATCH PHARMACEUTICALS (OTCBB: WSCH)*
>
> <http://www.businessworldwide.net/sik/spacer.gif>
>
>
><http://us.f1.yahoofs.com/users/15e54a78/bc/bosko+family/__tn_arrow25.gif?bcKX9t8ANyXtRQyZ>
>
>
>
> TOP 4 REASONS TO BUY WSCH
>
> <http://www.businessworldwide.net/sik/spacer.gif>
> *1.* The products and medical therapies developed by WSCH represent
> possibly the *most important breakthrough* in the field of Dermatology
> in the last fifty years.
> *2.* WSCH anticipates *FDA approval* on seven over-the-counter products
> within the next year, which will provide significant revenue in the
> retail drug market.
> *3.* WSCH has experienced a *success rate of 90%* during clinical
> studies, completely eliminating skin disease from 90% of all patients
> treated.
> *4.* By year five, WSCH plans to have annualized revenue over *$525
> million* and over *$125 million in EBIT*. This does not take into
> account income from OTC products which will be substantial.
>
>
>
>
><http://us.f1.yahoofs.com/users/15e54a78/bc/bosko+family/__tn_arrow25.gif?bcKX9t8ANyXtRQyZ>
>
>
>
> PROJECTIONS, OBJECTIVES AND STATISTICS
>
> Over a
> five year period, AISC (WSCH's subsidiary) plans to establish *350
> clinics in over 100 major population areas*. The company plans to hire
> over 150 medical doctors for these clinics, train over 1,000 medical
> assistants and treat over *2,000,000 patients*. Also by year five, WSCH
> plans to have annualized over _$525 million in revenue and over $125
> million in EBIT_. This does not take into account income from OTC
> products which will be substantial.
>
> As of 1991, there were approximately *14 million *chronic acne and
> eczema patients annually in the United States, with the highest
> percentage between 18 to 44 years of age. The actual number of patients
> with any type of acne Is significantly higher. *Seven billion dollars is
> spent annually *on dermatological pharmaceutical products for these
> disorders.
>
> In 1994, the teen population reached 25 million. During the next decade,
> it will grow at *nearly twice the rate of the overall population*
> (according to U.S. Census Bureau projections). Acne patients are
> primarily teenagers, whereas eczema patients range from infants to
> the elderly.
>
> * SYMBOL:* * WSCH*
> * CURRENT PRICE:* *$0.0**59*
> * 52 WEEK HIGH:* *$27.50*
> * 52 WEEK LOW:* * $0.0**56*
>
> <http://www.businessworldwide.net/sik/spacer.gif>
>
>
><http://us.f1.yahoofs.com/users/15e54a78/bc/bosko+family/__tn_arrow25.gif?bcKX9t8ANyXtRQyZ>
>
>
>
> COMPANY BACKGROUND
>
> Wasatch Pharmaceutical, Inc. is a fourteen year old company with a
> record of outstanding achievements in the field of Dermatology.
> Dermatology. Under the name of its subsidiary, American Institute of
> Skin Care *(AISC)*, Wasatch has operated two prototype clinics for the
> last five years where the products and medical therapies have been
> tested and proven on hundreds of patients. The Company's activities have
> been centered on research in the area of *serious skin diseases*. A
> concurrent discovery and benefit is WSCH's dramatic success in the area
> of skin rejuvenation.
>
> Seeing the high growth potential from major funding, WSCH elected to
> *become a public company* less than two years ago.
>
> Wasatch's major successes in the area of skin diseases include:
>
> *Cystic Acne, Eczema, Seborrhea, Contact Dermatitis, Molluscum,
> Folliculitis, Acne Rosacea and less prevalent skin diseases.*
> Interestingly, these skin disorders account for more than *70% of all
> business* in the field of dermatology for which there are very few (if
> any) safe, effective therapies like those developed by *Wasatch.*
> Because the therapies developed by Wasatch *dominate* this area of
> medicine, WSCH has elected to market its products via company-owned
> clinics throughout the United States. This decision has resulted in the
> establishment of *two research clinics* in Utah for the purpose of
> implementing procedures within the clinics pursuant to testing and
> confirming the results that were achieved in past clinical trials. Due
> to its *success rate of 90% on hundreds of patients over a five year
> period*, WSCH's clinics are now on line with insurance providers
> independent of HMOs. Efforts to establish Preferred Providership status
> with HMOs are presently being pursued.
>
> *THIS JUST IN : WSCH BREAKING NEWS*
>
>
>
>
> Wasatch Pharmaceutical Inc. Announces a New Physician Marketing
> Campaign and Listing On German Stock Exchanges
>
>
> MURRAY, Utah--(BUSINESS WIRE)--Nov. 27, 2001--Wasatch Pharmaceutical
> Inc. (OTCBB:WSCH <http://finance.yahoo.com/q?s=wsch.ob&d=t> - news
> <http://biz.yahoo.com/n/w/wsch.ob.html>) CEO Gary Heesch announced
> today a marketing campaign directed to physicians. A direct link has
> been established on a physician recruiting Web site making available
> therapies for the treatment of cystic acne, acne, folliculitis and
> skin rejuvenation. Physicians will find the benefits of these
> treatment therapies by logging on to the *"X Acne" link at the
> Physician Search website*. This physician search Web site typically
> receives over *200,000 hits per month*. Mr. Heesch reminded, "Our
> treatment therapy products are also available via the AISC Online
> Store."
>
> These skin treatment products come in kit form providing a 90-day supply
> to patients for the full treatment program. Included in the kit is an
> instructional video on the treatment therapy allowing the patient to use
> these products in their home. The therapies, when used as instructed,
> achieve a *success rate of eradication in excess of 90% with no side
> effects of any consequence*. Previously, these therapies and associated
> products were only available through the two prototype clinics in Utah.
> The availability of these products will open the way for family
> practitioners, pediatricians, internists and other primary care
> physicians to retain their patients under their care during the
> treatment of these common skin disorders. *The benefit to insurance
> providers is the potential to save millions of dollars in reimbursement
> costs by freeing the physician and the patient from ongoing treatment.*
>
> In the coming year, _six additional therapies will be made available_
> for a broad range of skin disorders that are badly in need of successful
> therapies.
>
> Gary Heesch also announced the listing of Wasatch Pharmaceutical stock
> on the *Frankfurt and Berlin Exchanges in Germany*. Active trading on
> these exchanges will take place upon the completion of a research report
> in Germany. Said Mr. Heesch, "We feel this is a significant event as
> Wasatch will gain *wider exposure* as a leader in dermatology and will
> put _buying_ _pressure on its stock to *reflect the true value* _of a
> company that has committed years of research and development of products
> that allow people with serious skin disorders to live normal and more
> productive lives."
>
> /There may be forward-looking statements in this release. Investors are
> cautioned that such forward-looking statements involve risks and
> uncertainties, including, without limitation, continued acceptance of
> the Company's products, increased levels of competition, new products
> introduced by competitors, changes in the rates of subscriber
> acquisition and retention, and other risks detailed from time to time in
> the Company's periodic reports filed with the Securities and Exchange
> Commission./
>
> *A LOOK AT THE COMPETITION*
>
> Dermatologists are the primary competitors of WSCH's clinics.
> Dermatologists specialize in the treatment of skin disorders and
> prescribe medications to treat the disorder. However, competing products
> address the *symptoms* of acne and eczema, *not the cause. *
>
> The competition's skin care treatments include prescription medications
> (oral and external use drugs prescribed by dermatologists and other
> doctors) and over-the-counter products.
>
> *Several common prescription medications include: *
>
> 1) E-Mycin for oral and topical use, 2) Cleocin for oral and topical
> use, 3) Tetracycline for oral and topical use, and 4) Accutane for oral
> use only.
>
> *Over-the-counter acne medications include: *
> 1) Clearasil and Oxy creams, 2) generic brand creams, 3) medicated pads,
> and 4) medicated soaps.
>
> /_Many of the competition's oral medications have serious side effects._/
>
> Costs for competing treatments range from $2.50 for medicated soaps to
> $200 for Accutane oral medication prescription. Treatments are
> on-going. Over time a person can spend an *unlimited amount of money* on
> such treatments. An example would be someone who spent $1,500 for a 22
> week program of Accutane which includes blood testing. Another example
> would be someone who has had acne for many years and has spent in excess
> of $34,000.
>
> At this time there is *no known competitor *who treats the causes of
> these skin disorders and no competitor can claim a *success rate* equal
> to that of Wasatch's treatments.
>
> *A FINAL WORD ABOUT WSCH*
>
> With a proven success rate of 90% in a field that affects so many of our
> lives, Wasatch has clearly positioned itself in a market *hungry and
> desperate* for successful products and treatment. WSCH has recently
> expanded its marketing presence (as seen in the above press release) and
> will continue to aggressively broaden awareness over the near term. The
> listing of *WSCH* on the German stock exchange is another sign of the
> company's credibility and ambitious plans to establish itself as a
> *major global player* in the field of dermatology.
>
> * *WSCH has taken on a completely different approach. By addressing the
> causes of skin disorders rather than the symptoms, WSCH will help to
> successfully eliminate skin disease altogether. Given the following:
>
> 1. Successful 14-year history and plans for expansion
> 2. Impressive revenue projections ($525 million+ annualized by year 5
> and $125 million in EBIT)
> 3. Virtually unmatched success rate of 90%...
>
> ...*and so much more, WSCH will certainly be watched by savvy investors
> for some time to come.*
>
> *To be removed from future mailings, please reply to this email with
> "Remove" in the subject line*
>
> *
> *DISCLAIMER:
> Information within this email contains "forward looking statements"
> within the meaning of Section 27A of the Securities Act of 1933 and
> Section 21B of the Securities Exchange Act of 1934. Any statements that
> express or involve discussions with respect to predictions,
> expectations, beliefs, plans, projections, objectives, goals,
> assumptions or future events or performance are not statements of
> historical fact and may be "forward looking statements."
>
> Forward looking statements are based on expectations, estimates and
> projections at the time the statements are made that involve a number
> of risks and uncertainties which could cause actual results or events to
> differ materially from those presently anticipated. Forward looking
> statements in this action may be identified through the use of words
> such as "projects", "foresee", "expects", "will," "anticipates,"
> "estimates," "believes," "understands" or that by statements indicating
> certain actions "may," "could," or "might" occur. All information
> provided within this email pertaining to investing, stocks, securities
> must be understood as information provided and not investment advice.
> Emerging Growth Stock Alert advises all readers and subscribers to
> seek advice from a registered professional securities representative
> before deciding to trade in stocks featured within this email. None of
> the material within this report shall be construed as any kind of
> investment advice.
>
> In compliance with the Securities Act of 1933, Section17(b), Emerging
> Growth Stock Alert discloses the receipt of $50,000 cash from a third
> party for the publication of this report and additional services related
> to WSCH. Be aware of an inherent conflict of interest resulting from
> such compensation. In addition, Emerging Growth Stock Alert intends to
> receive three million five hundred thousand unrestricted shares of WSCH
> from a third party for the publication of this report and additional
> services related to WSCH. Be aware of an inherent conflict of interest
> due to our intent to profit from the liquidation of these shares. Part
> or all of this position may be sold at any time, even after we have made
> positive statements regarding the above company. All factual
> information in this report was gathered from public sources, including
> but not limited to SEC filings, Company Press Releases, and the
> company's website at wasatchpharm.com. Emerging Growth Stock Alert
> believes this information to be reliable but can make no guarantee as to
> its accuracy or completeness. Use of the material within this email
> constitutes your acceptance of these terms.
>
>
> *To be removed from future mailings, please reply to this email with
> "Remove" in the subject line*
>
